Photo of Leo L. Cheng,  MPP, PhD

Leo L. Cheng, MPP, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-6593
Fax: (617) 726-5684


cheng@nmr.mgh.harvard.edu

Leo L. Cheng, MPP, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Radiology, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research aim at measuring NMR spectra of intact tissue specimens and correlating tissue cellular metabolic changes with its pathology. The current research projects include NIH funded studies of human brain tumors and prostate cancer.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Gouveia GJ, Head T, Cheng LL, Clendinen CS, Cort JR, Du X, Edison AS, Fleischer CC, Hoch J, Mercaldo N, Pathmasiri W, Raftery D, Schock TB, Sumner LW, Takis PG, Copié V, Eghbalnia HR, Powers R. Perspective: use and reuse of NMR-based metabolomics data: what works and what remains challenging. Metabolomics 2024; 20:41. PubMed
  • Broeckling CD, Beger RD, Cheng LL, Cumeras R, Cuthbertson DJ, Dasari S, Davis WC, Dunn WB, Evans AM, Fernández-Ochoa A, Gika H, Goodacre R, Goodman KD, Gouveia GJ, Hsu PC, Kirwan JA, Kodra D, Kuligowski J, Lan RS, Monge ME, Moussa LW, Nair SG, Reisdorph N, Sherrod SD, Ulmer Holland C, Vuckovic D, Yu LR, Zhang B, Theodoridis G, Mosley JD. Current Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples. Anal Chem 2023; 95:18645-18654. PubMed
  • Huynh MJ, Gusev A, Palmas F, Vandergrift L, Berker Y, Wu CL, Wu S, Cheng LL, Feldman AS. Characterization of the metabolomic profile of renal cell carcinoma by high resolution magic angle spinning proton magnetic resonance spectroscopy. Urol Oncol 2023. PubMed
  • Hasubek AL, Wang X, Zhang E, Kobus M, Chen J, Vandergrift LA, Kurreck A, Ehret F, Dinges S, Hohm A, Tilgner M, Buko A, Habbel P, Nowak J, Mercaldo ND, Gusev A, Feldman AS, Cheng LL. Differentiation of patients with and without prostate cancer using urine H NMR metabolomics. Magn Reson Chem 2023. PubMed
  • Berker Y, Muti IH, Cheng LL. Visualizing metabolomics data with R. NMR Biomed 2022. PubMed
  • Cardoso MR, Silva AAR, Talarico MCR, Sanches PHG, Sforça ML, Rocco SA, Rezende LM, Quintero M, Costa TBBC, Viana LR, Canevarolo RR, Ferracini AC, Ramalho S, Gutierrez JM, Guimarães F, Tasic L, Tata A, Sarian LO, Cheng LL, Porcari AM, Derchain SFM. Metabolomics by NMR Combined with Machine Learning to Predict Neoadjuvant Chemotherapy Response for Breast Cancer. Cancers (Basel) 2022. PubMed
  • Wishart DS, Cheng LL, Copié V, Edison AS, Eghbalnia HR, Hoch JC, Gouveia GJ, Pathmasiri W, Powers R, Schock TB, Sumner LW, Uchimiya M. NMR and Metabolomics-A Roadmap for the Future. Metabolites 2022. PubMed
  • Steiner A, Schmidt SA, Fellmann CS, Nowak J, Wu CL, Feldman AS, Beer M, Cheng LL. Ex Vivo High-Resolution Magic Angle Spinning (HRMAS) H NMR Spectroscopy for Early Prostate Cancer Detection. Cancers (Basel) 2022. PubMed
  • Sanchez-Dahl Gonzalez M, Muti IH, Cheng LL. High resolution magic angle spinning MRS in prostate cancer. MAGMA 2022. PubMed
  • Zhong AB, Muti IH, Eyles SJ, Vachet RW, Sikora KN, Bobst CE, Calligaris D, Stopka SA, Agar JN, Wu CL, Mino-Kenudson MA, Agar NYR, Christiani DC, Kaltashov IA, Cheng LL. Multiplatform Metabolomics Studies of Human Cancers With NMR and Mass Spectrometry Imaging. Front Mol Biosci 2022; 9:785232. PubMed
  • Firdous S, Abid R, Nawaz Z, Bukhari F, Anwer A, Cheng LL, Sadaf S. Dysregulated Alanine as a Potential Predictive Marker of Glioma-An Insight from Untargeted HRMAS-NMR and Machine Learning Data. Metabolites 2021. PubMed
  • Schult TA, Lauer MJ, Berker Y, Cardoso MR, Vandergrift LA, Habbel P, Nowak J, Taupitz M, Aryee M, Mino-Kenudson MA, Christiani DC, Cheng LL. Screening human lung cancer with predictive models of serum magnetic resonance spectroscopy metabolomics. Proc Natl Acad Sci U S A 2021. PubMed
  • Berker Y, Vandergrift LA, Wagner I, Su L, Kurth J, Schuler A, Dinges SS, Habbel P, Nowak J, Mark E, Aryee MJ, Christiani DC, Cheng LL. Magnetic Resonance Spectroscopy-based Metabolomic Biomarkers for Typing, Staging, and Survival Estimation of Early-Stage Human Lung Cancer. Sci Rep 2019; 9:10319. PubMed
  • Dinges SS, Hohm A, Vandergrift LA, Nowak J, Habbel P, Kaltashov IA, Cheng LL. Cancer metabolomic markers in urine: evidence, techniques and recommendations. Nat Rev Urol 2019; 16:339-362. PubMed
  • Dinges SS, Vandergrift LA, Wu S, Berker Y, Habbel P, Taupitz M, Wu CL, Cheng LL. Metabolomic prostate cancer fields in HRMAS MRS-profiled histologically benign tissue vary with cancer status and distance from cancer. NMR Biomed 2019. PubMed
  • Tilgner M, Vater TS, Habbel P, Cheng LL. High-Resolution Magic Angle Spinning (HRMAS) NMR Methods in Metabolomics. Methods Mol Biol 2019; 2037:49-67. PubMed
  • Vandergrift LA, Decelle EA, Kurth J, Wu S, Fuss TL, DeFeo EM, Halpern EF, Taupitz M, McDougal WS, Olumi AF, Wu CL, Cheng LL. Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue. Sci Rep 2018; 8:4997. PubMed
  • Kurreck A, Vandergrift LA, Fuss TL, Habbel P, Agar NYR, Cheng LL. Prostate cancer diagnosis and characterization with mass spectrometry imaging. Prostate Cancer Prostatic Dis 2017. PubMed
  • Decelle EA, Cheng LL. High-resolution magic angle spinning 1H MRS in prostate cancer. NMR Biomed 2014. PubMed
  • Spur EM, Decelle EA, Cheng LL. Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry. Eur J Nucl Med Mol Imaging 2013. PubMed
  • DeFeo EM, Cheng LL. Characterizing human cancer metabolomics with ex vivo 1H HRMAS MRS. Technol. Cancer Res. Treat. 2010; 9:381-91. PubMed
  • Maxeiner A, Adkins CB, Zhang Y, Taupitz M, Halpern EF, McDougal WS, Wu CL, Cheng LL. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate 2010; 70:710-7. PubMed
  • Kaul D, Wu CL, Adkins CB, Jordan KW, Defeo EM, Habbel P, Peterson RT, McDougal WS, Pohl U, Cheng LL. Assessing prostate cancer growth with mRNA of spermine metabolic enzymes. Cancer Biol Ther 2010; 9:736-42. PubMed
  • Wu CL, Jordan KW, Ratai EM, Sheng J, Adkins CB, Defeo EM, Jenkins BG, Ying L, McDougal WS, Cheng LL. Metabolomic imaging for human prostate cancer detection. Sci Transl Med 2010; 2:16ra8. PubMed
  • Jordan KW,Nordenstam J,Lauwers GY,Rothenberger DA,Alavi K,Garwood M,Cheng LL. Metabolomic characterization of human rectal adenocarcinoma with intact tissue magnetic resonance spectroscopy. Dis Colon Rectum 2009; 52:520-5. PubMed
  • Jordan KW, Cheng LL. NMR-based metabolomics approach to target biomarkers for human prostate cancer. Expert Rev Proteomics 2007; 4:389-400. PubMed
Hide